Direct Actions of AT <sub>1</sub> (Type 1 Angiotensin) Receptors in Cardiomyocytes Do Not Contribute to Cardiac Hypertrophy
نویسندگان
چکیده
Activation of AT 1 (type Ang) receptors stimulates cardiomyocyte hypertrophy in vitro. Accordingly, it has been suggested that regression cardiac associated with renin-Ang system blockade is due to inhibition cellular actions Ang II the heart, above and beyond their effects reduce pressure overload. We generated 2 distinct mouse lines cell-specific deletion 1A receptors, from cardiomyocytes. In first line (C-SMKO), elimination was achieved using a heterologous Cre recombinase transgene under control Sm22 promoter, which expresses cells smooth muscle lineage including cardiomyocytes vascular conduit but not resistance vessels. The second (R-SMKO) utilized knocked-in locus, drives expression myocytes both arteries. Thus, although groups lack cardiomyocytes, they are distinguished by presence (C-SMKO) or absence peripheral responses II. Similar wild-types, chronic infusion caused hypertension C-SMKO mice, whereas were reduced R-SMKOs. despite C-SMKOs develop robust hypertrophy. By contrast, R-SMKOs developed identical levels response overload–induced transverse aortic banding. Our findings suggest direct activation minimal influence on induced
منابع مشابه
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
Angiotensin type 1 (AT1) receptor blocker (ARB) ameliorates progression of chronic kidney disease. Whether this protection is due solely to blockade of AT1, or whether diversion of angiotensin II from the AT1 to the available AT2 receptor, thus potentially enhancing AT2 receptor effects, is not known. We therefore investigated the role of AT2 receptor in ARB-induced treatment effects in chronic...
متن کاملOverexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.
Angiotensin II (AII) is a major determinant of arterial pressure and volume homeostasis, mainly because of its vascular action via the AII type 1 receptor (AT1R). AII has also been implicated in the development of cardiac hypertrophy because angiotensin I-converting enzyme inhibitors and AT1R antagonists prevent or regress ventricular hypertrophy in animal models and in human. However, because ...
متن کاملThe angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.
Angiotensin II (Ang II) has important actions on the heart via type 1 (AT1) and type 2 (AT2) receptors. The link between AT1 receptor activation and the hypertrophy of cardiomyocytes is accepted, whereas the contribution of the AT2 receptor, which reportedly antagonizes the AT1 receptor, is contentious. This ambiguity is primarily based on in vivo approaches, in which the direct effect of the A...
متن کاملResveratrol Suppresses Cardiac Renin Angiotensin System in the Late Phase of Left Ventricular Hypertrophy
Background and objectives: Resveratrol(3,5,4′-trihydroxy-trans-stilbene) is a natural polyphenole phytoalexin which exerts potential cardioprotective effects, but the cellular and molecular mechanisms responsible for these effects are still unknown. Cardiac renin angiotensin system (RAS) over-activation plays an important role in pathogenesis of left ventricula...
متن کاملPerformance of electrophysiologic study in an asymptomatic patient with type 2 intermittent Brugada syndrome: To do or not to do?
Background: Brugada syndrome (BrS) is an inherited channelopathy, which is associated with sudden cardiac death due to rapid polymorphic VT or VF. There is no definite consensus regarding the management of asymptomatic patients. Some experts advocate close follow-up; others propose the programmed stimulation for risk stratification. We aimed to evaluate the benefit of complete atrial and ventri...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hypertension
سال: 2021
ISSN: ['1524-4563', '0194-911X']
DOI: https://doi.org/10.1161/hypertensionaha.119.14079